- Papers for Project Outcome
- Other Project Outcomes
The FNCA FY2017 Workshop on Radiation Oncology
FNCA 2017 Workshop on Radiation Oncology
Manila, the Philippines
Outline of Workshop
i) Date : October 25th-28th , 2017
ii) Venue : Manila, the Philippines
iii) Host Organization : Jose R. Reyes Memorial Medical Center (JRRMMC)
Philippine Nuclear Research Institute (PNRI)
Ministry of Education, Culture, Sports, Science and Technology(MEXT)
iv) Participants :
Bangladesh, China, Indonesia, Japan, Kazakhstan, Korea, Malaysia, Mongolia, Philippines, Thailand, Vietnam.
The FNCA 2017 Workshop on Radiation Oncology was held from 25 to 28 October, 2017 in Manila, the Philippines. The workshop was co-organized by Jose R. Reyes Memorial Medical Center (JRRMMC), Philippine Nuclear Research Institute (PNRI) and the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT). Representatives from 11 FNCA member countries, namely Bangladesh, China, Indonesia, Japan, Kazakhstan, Korea, Malaysia, Mongolia, the Philippines, Thailand and Vietnam participated in the workshop.
This project carries out some international joint clinical studies in order to establish treatment protocols for Uterine Cervix cancer, Nasopharyngeal cancer and Breast cancer, which affect large number of people in FNCA member countries, and finally to improve the technique of radiation oncology in the Asian region.
Dr. Miriam Joy Calaguas, Chairman, Department of Radiotherapy, JRRMMC moderated the session. She officially opened the workshop and reviewed the history of this project.
Dr. Soledad S. Castaテアeda, FNCA Coordinator of the Philippines welcomed the participants with her remarks.
Mr. Tomoaki WADA, FNCA Coordinator of Japan gave the opening address.
Prof. Shingo KATO, the Project Leader of Radiation Oncology Project gave his remarks and keynote address.
Dr. Carlo A. Arcilla, Director of Philippine Nuclear Research Institute (PNRI) gave his remarks.
Dr. Yuichi MICHIKAWA, MEXT also gave his remarks and introduced the FNCA and Human Resource Development programs implemented by the Japanese Government.
Dr. Dennis V. Doromal, President of Philippines Radiation Oncology Society (PROS), delivered a special lecture on the Overview of Radiation Oncology in the Philippines.
Phase II Study of Concurrent Chemoradiotherapy with Extended-Field Radiotherapy for Locally Advanced Cervical Cancer (CERVIX-IV)
In this protocol, 106 patients were registered from all the countries at the point of this workshop. The 106 cases were consisted of Bangladesh (32), China (8), Indonesia (9), Japan (20), Kazakhstan (1), Korea (7), Malaysia (5), Mongolia (8), Philippines (4), Thailand (4) and Vietnam (8).
12 cases (out of 106 cases ) were not evaluable.
Of the 94 evaluable cases: 50 patients had stage IIB disease and 44 had stage IIIB disease. All patients had positive pelvic lymph node (PLN) and negative paraaortic lymph node (PALN) assessed by CT or USN. Median overall treatment time was 57 days. Mean dose to point A was 81.9 Gy. Seventy six (81 %) patients received > 4 cycles of chemotherapy. Grade 3 leukopenia occurred in 19 patients (20%), 1 patient developed grade 4 neutropenia. For late toxicity, sigmoid/rectum grade 3 toxicity was observed in 2 patients, small bowel grade 3 toxicity was observed in 2 patients. The 2-year follow-up rate was 97%. The 2-year and 5-year local control (LC) rates were 96% and 91%, respectively. The 2-year and 5-year progression free survival (PFS) rates were 77% and 65%, respectively. The 2-year and 5-year overall survival (OS) rates were 91% and 77%, respectively.
An open discussion on the clinical data of Cervix-IV followed. The result of Cervix-IV is better than Cervix-III, patients with distant metastases decreased. On the other hand, follow-up of patients need CT. Preliminary analysis showed no difference in OS between stage IIB and IIIB. Prophylactic paraaortic lymph node irradiation showed good result without increasing toxicity.
Prospective Observational Study of 3D-Image guided brachy therapy for Locally Advanced Cervical Cancer (CERVIX-V)
The new protocol for a cervical cancer, Cervix-V" was reviewed. This protocol was approved by the Institutional Review Board (IRB) in NIRS in May 2017.Each country spoke about the current preparation state, present problems and difficulties to work on CERVIX-V.
Bangladesh: 2 centers are planning to join, in one IRB was already approved, one still in preparation. Proposed the necessity of hands-on training and QC of follow-up.
China: IRB papers being prepared.
Indonesia: IRB approved in one institute, one institute pending.
Kazakhstan: IRB approved in one institute, one patient enrolled.
Korea: IRB papers under translation and due for submission. The protocol may conflict with ongoing clinical trials.
Malaysia: IRB approved in one institute.
Mongolia: 3D-IGBT not yet available, implementation project on-going.
Philippines: IRB submission revised and waiting approval.
Thailand: IRB papers under translation.
Viet Nam: IRB papers yet to be submitted.
Discussion on CERVIX-V followed. The use of IMRT for whole pelvis irradiation was accepted in the trial. It was confirmed that no chemotherapy in adjuvant nor neoadjuvant setup is to be allowed and concurrent chemotherapy other than cisplatin is also not acceptable. It was also emphasized that each brachytherapy session is to be done with 3D image guidance.
All member states agreed on the necessity of on-site training, but the framework was an issue. Prof. Kato proposed a framework for on-site training; conducting 3D-IGBT on-site training during FNCA WS on Radiation Oncology annual meeting.
QA/QC for 3D-IGBT
This activity aims to put in place reliable dosimetry in the institutes among the member countries for effective joint clinical studies. The audits in QA/QC of dosimetry measurement and radiation calibration have been conducted, which is for the reliable radiotherapy.
Along with the initiation of CERVIX-V, this QA/QC activity also focuses on the brachytherapy.
The plans of auditing 3D-IGBT were presented by Japan. The following aspects were mentioned for audit: applicator commissioning, source position confirmation, and source calibration. In order to conduct these procedures, a newly designed water phantom is currently being prepared.
Mr. Julius Cezar ROJALES, Senior Medical Physicist and Vice President for Ancillary Services, St. Luke窶冱 Medical Center presented the current status of 3D-IGBT in the Philippines.
The current progress of Electronic Data Capture system preparation was reported. While some problems are yet to be fixed, website is operational and member state are encouraged to access the website and to report any difficulties.
Phase II Study of Neoadjuvant Chemotherapy with Concurrent Chemoradiotherapy (CCRT) for Nasopharyngeal Carcinoma (NPC-III)
A total 108 patients have been registered in this protocol at the time of this workshop. Out of 108 cases, 43 cases were newly registered this year. The 65 cases were consisted of Bangladesh (1), China (8), Indonesia (12), Japan (0), Kazakhstan (0), Korea (0), Malaysia (25), Mongolia (0), Philippines ( 7 ) Thailand (0) and Vietnam (55).
Median follow up was 38 months (2-73). Median age was 47 years. All patients had 2 -3 cycles of neoadjuvant chemotherapy for a compliance rate of 100%, while concurrent chemotherapy had 75% compliance rate for 4 cycles or more. Median overall treatment time of radiotherapy was 55 days (range 44 - 232 days). Radiotherapy treatment interruption of >14 days occurred in 29% of patients mainly due to machine breakdown, re-planning and toxicities. In the neoadjuvant phase, grade 3/4 hematological toxicities occurred in 16% of patients and non-hematological toxicities in 22%. During the concurrent phase, grade 3/4 hematological toxicities occurred in 25% of patients and non-hematological toxicities in 34%. Late toxicities of grade 3 occurred in 10% of patients, mainly salivary gland and subcutaneous tissue toxicities.
Efficacy results: 3-year survival results: OS was 73%. Loco-regional failure was 22%. Distant metastasis free rate (DMF) was 78%. PFS was 70%. When compared with the results from NPC-I study, these results showed better rates in DMF and OS but worse rates in local control, but all of which were not statistically significant. Failure was mainly in the distant metastasis sites (17%) but this figure is lower compared to NPC-I study (28%).
The target enrolment is 120 patients and 108 were accrued so far.
As the target is nearly achieved, it was decided to continue with enrolment for one more year. The data center will communicate with participating centers closely to monitor accrual and to inform when target accrual is achieved.
Phase II Study of Hypofractionated Radiotherapy for Breast Cancer (Postmastectomy Radiation Therapy (PMRT)/BREAST-I)
In this session, a protocol PMRT/BREAST-I was reviewed and the following numbers were reported. Bangladesh (77), China (13), Indonesia (2), Japan (8), Kazakhstan (36), Korea (0), Malaysia (0), Mongolia (25), Philippines (10), Thailand (0) and Vietnam (0).The total number of PMRT patients were 171.
Overall 171 patients in HF-PMRT arm were enrolled during 56 months. Evaluable number of patients was 164. All patients completed protocol treatment. The median age was 49 years old (range, 24-80). Ninety-two patients (56%) had right-sided breast cancer. The clinical stage was IIA in 65 patients (40%), IIB in 60 (37%), IIIA in 35 (21%), IIIB in 3 (2%), and IIIC in 1 (1%), respectively. The median treatment duration was 21 days (range, 16-256). Seven patients experienced treatment interruption. Acute dermatitis of grade 2 or higher was observed in 3 patients (1%) and grade 1 acute subcutaneous toxicity was observed in 16 patients (10%). Acute grade 1 cardiac toxicity was observed in 3 patients (2%) and late grade 1 cardiac toxicity in 4 patients (2%). Late grade 1 lung toxicity was observed in 11 patients (7%). Five loco-regional recurrence, 13 distant metastases and 8 breast cancer deaths had been observed.
An open discussion on the clinical data followed. Some data are missing or wrongly written in the registration sheet. All co-investigators are advised to re-check their data and send corrected data. Co-investigators are encouraged to enroll patients until next year.
Phase II Study of Hypofractionated Radiotherapy for Breast Cancer (Whole Breast Irradiation / BREAST-I)
In this session, a protocol WBI/BREAST-I was reviewed and the following numbers were reported. Bangladesh (31), China (6), Indonesia (16), Japan (138), Kazakhstan (14), Korea (10), Malaysia (0), Mongolia (3), Philippines (0), Thailand (16) and Vietnam (0). Total number of WBI patients was 234. (234 patients / 235 breast lesions).
Overall 235 breast lesions in HF-WBI arm were enrolled in 56 months. Only 226 breast lesions data were analyzable in this workshop. All the patients except one completed protocol treatment. The median age was 49 years (range, 24-79). One hundred fourteen patients (50%) had right-sided breast cancer. The clinical stage 0 was in 38 patients (17%), IA in 116 (51%), IB in 3 (1%), IIA in 49 (22%), and IIB in 20 (9%), respectively. One hundred sixty-three patients received boost radiotherapy to tumor bed. The median treatment duration was 26 days (range, 18-54). Only 8 patients experienced treatment interruption. Acute dermatitis of grade 2 or higher was observed in 26 patients (11%). In regards with the late toxicity, grade 2 lung toxicity was observed in 1 patient, grade 2 skin toxicity in 1 patient, and grade 2 subcutaneous toxicity in 1 patient. One loco-regional recurrence, 3 distant metastases, and 2 breast cancer death were observed.
An open discussion on the clinical data followed.
Some data are missing or probably wrongly filled out in registration sheet. All co-investigators need to re-check their data and send the corrected data. All co-investigators agreed on closing the registration.
Future Plan and Drafting the Workshop Minutes
Japan proposed on-site 3D-IGBT training course at FNCA WS and it was agreed by all of the FNCA member states. One / Two Radiation Oncologist and one / two Medical Physicist expert and also the local host will be in-charge of the onsite training course.
The next workshop is tentatively scheduled to be held in Bangladesh from November 11th 2018.
Technical Visit at St. Frances Cabirini Medical Center and St.Luke Medical Center
On the 3rd day, the WS participants conducted a Technical Visit to St. Frances Cabrini Medical Center (Batangas) and also visited St. Luke窶冱 Medical Center (Global City).
Open Lecture
On the 4th day, the Open Lecture was held in conjunction with the Postgraduate Course of the Department of Radiotherapy of JRRMMC. The theme was Global Issues in Radiation Oncology and was held at the Lung Center of the Philippines.
There were 5 lectures on the themes of 1) Overview and Introduction of FNCA, 2) Transition and Results of NPC protocols in HCM Cancer Hospital, 3)Are you ready to do Hypo Fractionation?,4) Role of IGBT in Cervical Cancer and 5) Overview: Advanced Technologies in Radiation Oncology in Asia Today. In addition to those lectures, a panel discussion on IGBT for a cervical cancer was held.
Prof. Shingo KATO concluded the morning session of Open Lecture with his closing remarks. The workshop was officially closed.
FNCA 2017 Workshop on Radiation Oncology Project
(1) Following the agreement at the 18th Forum for Nuclear Cooperation in Asia (FNCA) Coordinators Meeting, the FNCA FY2017 Workshop on Radiation Oncology was held from October 25th to 28th, 2017, in Manila, the Philippines. The meeting was co-organized by Jose R. Reyes Memorial Medical Center (JRRMMC), Philippine Nuclear Research Institute (PNRI) and the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT). Representatives from 11 FNCA member countries, namely Bangladesh, China, Indonesia, Japan, Kazakhstan, Korea, Malaysia, Mongolia, the Philippines, Thailand and Vietnam participated in the workshop.
(2) Dr. Miriam Joy Calaguas, Chairman, Department of Radiotherapy, JRRMMC moderated the session. She officially opened the workshop and reviewed the history of this project.
(3) Dr. Dennis V. Doromal, President of Philippines Radiation Oncology Society (PROS), delivered a special lecture on the Overview of Radiation Oncology in the Philippines. His talk covered the wide range of statistical data about cancer treatment in the Philippines.
(4) Introduction of individual participants followed.
(5) The agenda was adopted and chairpersons and rapporteurs were selected. (Annex 1)
Session 1: Phase II Study of Concurrent Chemoradiotherapy with Extended-Field Radiotherapy for Locally Advanced Cervical Cancer (CERVIX-IV)
(6) Dr. Noriyuki Okonogi, Section Chief, Gynecologic Tumor, National Institute of Radiological Science (NIRS) Hospital, National Institutes for Quantum and Radiological Science and Technology, Japan (QST), presented the protocol of Cervix IV, a Phase II Study of Concurrent Chemoradiotherapy with Extended-Field Radiotherapy for Locally Advanced Cervical Cancer.
An update on the clinical data of CERVIX-IV was presented by representatives of each participating country with the following number of patients: Bangladesh (32), China (8), Indonesia (9), Japan (20), Kazakhstan (1), Korea (7), Malaysia (5), Mongolia (8), Philippines (4), Thailand (4) and Vietnam (8). The total number of the patients was (106).
Dr. Okonogi then presented the summary of the follow-up data. As of today, a total of 106 cases were submitted for this study, 12 cases were not evaluable.
(7) An open discussion on the clinical data of Cervix-IV followed. The result of Cervix-IV is better than Cervix-III, patients with distant metastases decreased. On the other hand, follow-up of patients need CT. Preliminary analysis showed no difference in OS between stage IIB and IIIB. Prophylactic paraaortic lymph node irradiation showed good result without increasing toxicity.
Session 2: Prospective Observational Study of 3D-Image guided brachy therapy for Locally Advanced Cervical Cancer (CERVIX-V)
(8) Dr. OKONOGI introduced and reviewed the protocol of Cervix-V. The protocol was approved by the Institutional Review Board (IRB) in NIRS in May 2017.
(9) Each country spoke about the current preparation state, present problems and difficulties to work on CERVIX-V.
(10) Discussion on CERVIX-V followed. The use of IMRT for whole pelvis irradiation was accepted in the trial. It was confirmed that no chemotherapy in adjuvant nor neoadjuvant setup is to be allowed and concurrent chemotherapy other than cisplatin is also not acceptable. It was also emphasized that each brachytherapy session is to be done with 3D image guidance.
(11) All member states agreed on the necessity of on-site training, but the framework was an issue. Prof. Kato proposed a framework for on-site training; conducting 3D-IGBT on-site training during FNCA WS on Radiation Oncology annual meeting.
Session 3: QA/QC for 3D-IGBT
(12) Dr. Hideyuki MIZUNO, Senior Researcher, Department of Radiation Measurement and Dose Assessment, NIRS, QST, presented plans of auditing 3D-IGBT. The following aspects were mentioned for audit: applicator commissioning, source position confirmation, and source calibration. In order to conduct these procedures, a newly designed water phantom is currently being prepared.
(13) Mr. Julius Cezar ROJALES, Senior Medical Physicist and Vice President for Ancillary Services, St. Luke窶冱 Medical Center presented the current status of 3D-IGBT in the Philippines.
(14) Dr. Shigekazu FUKUDA, Section Manager, Radiation Quality Control Section, Clinical Research Cluster, NIRS, QST, reported the current progress of Electronic Data Capture system preparation. While some problems are yet to be fixed, website is operational and member state are encouraged to access the website and to report any difficulties.
Session 4: Phase II Study of Neoadjuvant Chemotherapy with Concurrent Chemoradiotherapy (CCRT) for Nasopharyngeal Carcinoma (NPC-III)
(15) Dr. Hirokazu MAKISHIMA, Attending Physician, Urological Tumor Section, NIRS, QST introduced the protocol of NPC-III, a Phase II Study of Neoadjuvant Chemotherapy with CCRT for Nasopharyngeal Carcinoma (NPC). Recent clinical data was presented by representatives of each participating country.
An update on the clinical data of NPC-III was presented by representatives of each participating country with the following number of patients: Bangladesh (1), China (8), Indonesia (12), Japan (0), Kazakhstan (0), Korea (0), Malaysia (25), Mongolia (0), Philippines (7) Thailand (0) and Vietnam (55). The total number of the patients was 108. New cases: 43.
(16) Dr. MAKISHIMA then presented the summary of the follow-up data.
Session 5: Phase II Study of Hypofractionated Radiotherapy for Breast Cancer (Postmastectomy Radiation Therapy (PMRT)/BREAST-I)
(17) Dr. Sawa KONO, Assistant Professor, Tokyo Women窶冱 Medical University introduced and reviewed the protocol of PMRT /BREAST-I.
(18) The clinical data of Phase II Study of Postmastectomy Radiation Therapy (PMRT) was presented by representatives of each participating countries. The following number of patients were reported: Bangladesh (77), China (13), Indonesia (2), Japan (8), Kazakhstan (36), Korea (0), Malaysia (0), Mongolia (25), Philippines (10), Thailand (0) and Vietnam (0). The total number of PMRT patients were 171.
(19) Prof. Kumiko KARASAWA, Professor and Chair, Department of Radiation Oncology, School of Medicine, Tokyo Women's Medical University presented the summary of the PMRT clinical data of breast cancer cases (171).
(20) An open discussion on the clinical data followed. Some data are missing or wrongly written in the registration sheet. All co-investigators are advised to re-check their data and send corrected data. Co-investigators are encouraged to enroll patients until next year.
Session 6: Phase II Study of Hypofractionated Radiotherapy for Breast Cancer (Whole Breast Irradiation / BREAST-I)
(21) Dr. Sawa KONO introduced and reviewed the protocol of Whole Breast Irradiation (WBI) / BREAST-I.
(22) The clinical data of Phase II Study of WBI was presented by representatives of each participating countries. The following numbers were reported: Bangladesh (31), China (6), Indonesia (16), Japan (138), Kazakhstan (14), Korea (10), Malaysia (0), Mongolia (3), Philippines (0), Thailand (16) and Vietnam (0). Total number of WBI patients was 234.
(23) Prof. Kumiko KARASAWA presented the summary of the WBI clinical data of breast cancer cases (234 patients / 235 breast lesions).
(24) An open discussion on the clinical data followed.
Session 7: Future Plan and Drafting the Workshop Minutes
(25) Prof Shingo Kato proposed on-site 3D-IGBT training course at FNCA WS and it was agreed by all of the FNCA member states. One / Two Radiation Oncologist and one / two Medical Physicist expert and also the local host will be in-charge of the onsite training course.
(26) The next workshop is tentatively scheduled to be held in Bangladesh from November 11th 2018.
(27) The draft of the minutes was submitted by rapporteurs, discussed and amended. The draft of the minutes will be circulated after the workshop and finalized.
(28) Prof. Shingo KATO summarized and commented on all the sessions.
Session 8: Technical Visit at St. Frances Cabirini Medical Center
(29)The participants conducted a Technical Visit to St. Frances Cabrini Medical Center (Batangas).
Session 9: Technical Visit at St. Luke窶冱 Medical Center
(30) The participants also visited St. Luke窶冱 Medical Center (Global City).
Session 10: Open Lecture
(31) The Open Lecture was held in conjunction with the Postgraduate Course of the Department of Radiotherapy of JRRMMC. The theme was Global Issues in Radiation Oncology and was held at the Lung Center of the Philippines.
(32) Dr. Elisa B. Valdez,Chief of the medical professional staff, JRRMMC welcomed the audience with her remarks and Dr. Miriam Joy Calaguas gave her opening remarks.
(33) Mr. Tomoaki WADA gave a lecture about the FNCA. He introduced its overview and spoke about the on-going 8 projects' activities and achievements.
(34) Dr. Dang Huy Quoc Thinh, Vice Director- Head of Radiation Oncology, Ho Chi Minh City Oncology Hospital introduced the transition and results of NPC protocols in his hospital.
(35) Prof. Kumiko KARASAWA gave a lecture entitled "Breast Cancer: Are you ready to do Hypo Fractionation?".
(36) Prof. Tatsuya OHNO, Professor / Medical Director, Heavy Ion Medical Center, Gunma University spoke on Role of IGBT in Cervical Cancer.
(37) A Panel Discussion on IGBT followed. Dr. Rey H. de los Reyes and Prof. Shingo KATO moderated the session. The panelist were Prof. Masaru WAKATSUKI (Japan) and Dr. Kullathorn Thephamongkhol (Thailand). They discussed a case of cervical cancer.
(38) The last lecture was delivered by Prof. Takashi NAKANO, Professor,
Gunma University Graduate School of Medicine. He gave a lecture on Overview: Advanced Technologies in Radiation Oncology in Asia Today.
(39) Prof. Shingo KATO concluded the morning session of Open Lecture with his closing remarks.
(40) The workshop was officially closed.
October 25th - 28th, 2017
Day 1 Wed, 25th October 2017
Place: Novotel Manila Araneta Center
Moderator: Dr. Miriam Joy Calaguas, Project Leader (Philippines)
- Dr. Soledad S. Castaneda, FNCA Coordinator (Philippines)
- Mr. Tomoaki WADA, FNCA Coordinator (Japan)
- Prof. Shingo Kato, Project Leader (Japan)
- Dr. Carlo A, Arcilla, Director of PNRI (Philippines)
Presentation: Outlines of FNCA & HRD Program Implemented by Japanese Government
- Dr. Yuichi MICHIKAWA, MEXT (Japan)
Special Lecture: Current Status of Radiation Oncology in the Philippines
- Dr. Dennis V. Doromal (Philippines), President of Philippines Radiation Oncology Society (PROS)
10:00-:10:05
Introduction of Members
Adoption of the Agenda
Group Photography
Session 1: Phase II Study of Concurrent Chemotherapy and Extended-Field Radiotherapy for Locally Advanced Cervical Cancer (CERVIX-IV)
Co-chairs: Dr. TO Anh Dung (Vietnam) & Dr. Henry Kodrat (Indonesia)
1) Introduction of the Protocol
- Dr. Noriyuki Okonogi (Japan)
2) Presentation on the clinical data from each country
- Bangladesh
- Indonesia
- Kazakhstan
- Korea
- Malaysia
- Mongolia
- The Philippines
- Viet Nam
3) Summary of the clinical data
4) Discussion (including drafting manuscript)
Session 2:Prospective Observational Study of 3D-Image-guided brachytherapy for Locally Advanced Cervical Cancer (CERVIX-V)
Co-chairs: Prof. Tatsuya Ohno (Japan) & Dr. A.F.M. Kamal Uddin (Bangladesh)
1) Introduction of 3D-IGBT/ Dr. Noriyuki Okonogi (Japan)
2) Country Report on Progress of the clinical study from each country
3) Discussion
15:20-16:30 Session 3: QA/QC for 3D-IGBT
Co-chairs: Mr. Bambang Haris Suhartono(Indonesia) & Dr. Kum Bae KIM (Korea ) &Mr. Pitchayut Nakkrasae (Thailand)
15:20-15:40 1) Plan of Audit of 3D-IGBT
- Dr. Hideyuki Mizuno (Japan)
15:40-16:00 2) 3D-IGBT in the Philippines
- Mr. Julius Cezar Rojales (Philippines)
16:00-16:10 3) Report on Database Construction for FNCA Clinical Data
- Dr. Shigekazu Fukuda (Japan)
16:10-16:30 4) Discussion
19:00-21:30 Welcome Dinner Hosted by Dr. Miriam Joy Calaguas
Day 2 Thu, 25th October 2017
Session 4: Phase II Study of Chemoradiotherapy for NPC (NPC-III)
Co-chairs: Dr. Lau Fen Nee (Malaysia) & Dr. Xu Xiaoting (China)
- Dr. Hirokazu Makishima (Japan)
10:00-10:20 Coffee Break
10:20-12:00 Session 5 :Phase II Study of Hypofractionated Radiotherapy for Breast Cancer (PMRT /BREAST-I)
Co-chairs: Dr. Navchaa Gombodorj (Mongolia) & Dr. Jaemelyn Marie O. Fernandez (Philippines)
1) Review and introduction of the Protocol
- Dr. Sawa Kono (Japan)
2) Presentation on the clinical data of PMRT from each country
- Prof. Kumiko Karasawa (Japan)
Session 6 :Phase II Study of Hypofractionated Radiotherapy for Breast Cancer (WBI /BREAST-I)
Co-chairs: Dr. Wonil JANG (Korea) & Prof. Tasbolat Adylkhanov (Kazakhstan) &Dr. Erdenetuya Yadamsuren (Mongolia)
- Dr. Sawa Kono (Japan )
2) Presentation on the clinical data of WBI from each country
15:00-18:00 Session 7 :Drafting the Workshop Minutes
Co-chairs: Prof. Cao Jianping (China) & Dr. Hirokazu Makishima (Japan) & Mr. Muzzamer Bin Mohammad Zahid (Malaysia)
1) Discussion (Review of WS & Future Plan)
2) Drafting WS Minutes
3) Summary of WS & Remarks /Prof. Shingo Kato (Japan) ,Project Leader
Day 3 Fri, 27th October 2017
07:30 Leave from Hotel
11:00 Lunch at Escala Hotel, Tagaytay
13:00-16:00 Session 8 : Technical Visit at St. Frances Cabrini Medical Center (Batangas)
Session 9: Technical Visit at St. Luke's Medical Center-(Global City)
Day 4 Sat, 28th October 2017
Place: Place: Lung Center of the Philippines
08:30-09:00 Registration
Session 10: Open Lecture (Joint Symposium with Global Issues in Radiation Oncology)
09:00-09:05 Welcome Remarks
- Dr. Elisa B. Valdez, Chief of the medical professional staff, JRRMMC
09:05-09:10 Opening Remarks
- Dr. Miriam Joy Calaguas, Chairman, Department of Radiotherapy JRRMMC
09:10-09:30 Introduction and Overview of FNCA
- Mr. Tomoaki WADA (Japan)
09:30-09:50 Transition and Treatment Results of NPC protocols (including FNCA protocols) in HCM Cancer Hospital /
- Dr. Dang Huy Quoc Thinh (Vietnam)
09:50-10:10 Breast Cancer: Are you ready to do Hypo Fractionation?
- Prof Kumiko Karasawa (Japan)
10:30-10:50 Cervical Cancer: Role of IGBT
- Prof. Tatsuy Ohno (Japan)
10:50-11:30 -Case Presentation on Cervical Cancer-
Moderators: Dr. Rey Delos Reyes (Philippines) & Prof. Shingo Kato (Japan) Panelists Prof. Masaru Wakatsuki (Japan) & Dr. Kullathorn Thephamongkhol (Thailand)
11:30-11:50 Overview: Advanced Technologies in Radiation Oncology in Asia Today
- Prof. Takashi Nakano (Japan)
11:50-12:00 Closing Remarks (for Morning Session) /Prof. Shingo KATO (Japan) Project Leader
13:00-17:00 Joint Symposium with Global Issues in Radiation Oncology by Local Lecturers
October 25th -28th, 2017
Dr.A.F.M.Kamal Uddin (Project Leader)
Assistant Professor, Radiation Oncology,
National Institute of Ear, Nose & Throat
Prof. CAO Jianping (Project Leader)
Professor / Director
School of Radiation Medicine and Protection,
Soochow University
Dr. XU Xiaoting
Radiation Oncologist/ Associate Professor /Vice-Director of the Departmnet of Radiation Oncology
The First Affiliated Hospital of Soochow University
Dr. Henry Kodrat (Project Leader)
Medical Staff, Radiotherapy Department,
Cipto Mangunkusumo Hospital
Mr. Bambang Haris Suhartono
Medical Physicist of Radiotherapy Department
Dr. Soetomo General Hospital
Mr. Tomoaki WADA
FNCA Coordinator of Japan
Prof. Shingo KATO (Project Leader)
Professor /Department of Radiation Oncology,
International Medical Center
Saitama Medical University
Prof. Takashi NAKANO
Gunma University Graduate School of Medicine
Prof. Kumiko KARASAWA
Department of Radiation Oncology, School of Medicine,
Tokyo Women窶冱 Medical University
Prof. Tatsuya OHNO
Professor / Medical Director
Heavy Ion Medical Center
Gunma University
Prof. Masaru WAKATSUKI
Department of Radiology,
Jichi Medical University
Dr.Shigekazu FUKUDA
Section Manager
Radiation Quality Control Section
Clinical Research Cluster
National Institute of Radiological Sciences (NIRS)
National Institutes for Quantum and Radiological Science and Technology (QST)
Dr.Hideyuki MIZUNO
Department of Radiation Measurement and Dose Assessment
National institute of Radiological Sciences(NIRS)
Dr. Noriyuki OKONOGI
Section Chief
Gynecologic Tumor, National Institute of Radiological Science (NIRS), Hospital,
National Institutes for Quantum and Radiological Science and Technology, Japan (QST)
Dr.Hirokazu MAKISHIMA
Urological Tumor Section
National Institute of Radiological Science (NIRS), Hospital
Dr.Sawa KONO
Dr.Yuichi MICHIKAWA
Office for Nuclear No- Proligeration Science and Technology
International Nuclear and Fusion Energy Affairs Division
Research and Development Bureau
Ministry of Education, Culture, Sports, Science and Technology,Japan (MEXT)
Ms. Ai YAMADA (Secretariat)
International Affairs and Research Department
Nuclear Safety Research Association (NSRA)
Prof.Tasbolat Adylkhanov
Chairman of Oncology and Visual Diagnostics Department
Semey State Medical University
Dr. Kum Bae KIM
Senior Researcher, Medical Physicist
Korea Institute of Radiological & Medical Sciences (KIRAMS)
Dr. Wonil JANG
Dr. Lau Fen Nee (Project Leader)
Senior Consultant / Clinical Oncologist
National Cancer Institute,Putrajaya, Malaysia
Mr. Muzzamer Bin Mohammad Zahid
Medical Physicist
Dr. Yadamsuren Erdenetuya
Radiation Oncologist of Raiothrapy Department
National Cancer Center of Mongolia
Dr. Navchaa Gombodorj
Molecular Pharmacology and Oncology Department
Dr.Miriam Joy CALAGUAS (PL)
Department of Radiotherapy,
Jose R. Reyes Memorial medical Center
Departmet of Radiation Oncology
St.Luke's Medical Center
Dr. Rey H. De Los Reyes
Institute of Medicine, Far Eastern University
Nicanor Reyes Medical Foundation (FEU-NRMF)
Professor & Senior Consultant,
Dept. of Obstetrics and Gynecology,
School of Medicine and Medical Center
Medical Specialist IV,
Depatment of Obstetrics and Gynecology,
Section of Gynecologic Oncology
Dr.Jaemelyn Marie O. Fernandez
Visiting Consultant
Dr. Kullathorn Thephamongkhol
Siriraj Hospital, Mahidol University
Mr.Pitchayut Nakkrasae
Dr. To Anh Dung
Head of Breast and Gynecology Radiotherapy Department,
National Cancer Hospital (K Hospital)
Dr.Dang Huy Quoc Thinh
Vice Director- Head of Radiation Oncology
Ho Chi Minh City Oncology Hospital